Anpocogin
- Generic Name
- Anpocogin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 3TTT9ZD93F
- Background
Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity.
- Indication
Investigated for use/treatment in thrombosis (deep vein), angina, coronary artery disease, and colorectal cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT04655586
- Locations
- 🇺🇸
ARCA Investigational Site #120, Tucson, Arizona, United States
🇦🇷ARCA Investigational Site #112, Rosario, Sante Fe, Argentina
🇦🇷ARCA Investigational Site #127, San Nicolás, Buenos Aires, Argentina
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
Phase 1
Suspended
- Conditions
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2008-05-07
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00443573
- Locations
- 🇺🇸
LAC/USC Medical Center, Los Angeles, California, United States
Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2006-11-29
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00116012
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath